Innovative theranostic Trop2 antibody-radionuclide conjugates (ARCs) for precision medicine

Theranostic antibody conjugates are an emerging class of therapeutics that combines an antibody with radionuclides that can both diagnose and treat disease. We have developed a site-specific Trop2 antibody-radionuclide conjugate (ARC), incorporating 89Zr for imaging and 225Ac for therapy. The imaging ARC, leveraging the long half-life of 89Zr, demonstrates strong tumor accumulation and favorable tumor-to-normal tissue (T/N) ratios across multiple xenograft models, including triple-negative breast cancer and non-small cell lung cancer. The therapeutic ARC, carrying an alpha-emitting radionuclide, effectively suppresses tumor growth in the corresponding xenograft models. This ARC is currently in preclinical development, with an investigational new drug (IND) application planned for 2026.